The transitional phase of multiple sclerosis: Characterization and conceptual framework.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 01 03 2020
revised: 17 05 2020
accepted: 24 05 2020
pubmed: 15 6 2020
medline: 15 5 2021
entrez: 15 6 2020
Statut: ppublish

Résumé

The conversion of relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) cannot be defined by a sharp threshold determined by event-based measures, but rather represents a gradual process. In consequence, there may exist a transitional phase between RRMS and clearly established SPMS. So far, transitional MS has been poorly characterized in terms of patient properties, course of disease and therapeutic interventions that may delay conversion to SPMS. Furthermore, the pathogenesis of transitional MS is incompletely understood, and no definitive imaging or laboratory test informs when exactly a patient has entered the transitional MS phase. Here we review the current knowledge and evidence characterizing the transitional phase of MS and propose potential designs and criteria for a prospective clinical study in patients with transitional MS.

Identifiants

pubmed: 32535501
pii: S2211-0348(20)30318-7
doi: 10.1016/j.msard.2020.102242
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102242

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Ingo Kleiter (I)

Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. Electronic address: ingo.kleiter@ms-klinik.de.

Ilya Ayzenberg (I)

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; Department of Neurology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Joachim Havla (J)

Institute of Clinical Neuroimmunology, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; Data Integration for Future Medicine consortium (DIFUTURE), Ludwig-Maximilians-Universität München, Munich, Germany.

Carsten Lukas (C)

Institute of Neuroradiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.

Iris-Katharina Penner (IK)

Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Christine Stadelmann (C)

Institute of Neuropathology, University Medical Center, Göttingen, Germany.

Ralf A Linker (RA)

Department of Neurology, University of Regensburg, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH